Of 1348 plasma samples, 1298 samples (96%) were negative for CMV DNA, meaning that less than 100 CMV DNA copies per ml plasma were detected. Fifty plasma samples (3.7%) were positive for CMV DNA (range 104–32088 copies/ml) with 100–1000, 1000–10 000 and 10 000–100 000 copies/ml in 37, nine and four samples respectively. CMV DNA more than 1000 copies/ml were found only in samples with detectable HIV-1 viral load (Table 1). Similarly, CMV DNA more than 1000 copies/ml were found only in samples with CD4 cell counts less than 250 × 106 cells/l (Table 1). Of all CMV positive samples, 33 (66%) were found in the first 3 months of HAART including 12 samples with CMV DNA more than 1000 copies/ml. Thereafter, the remaining 17 positive samples were equally distributed throughout the whole remaining period including 16 samples in the range 100–1000 copies/ml (e.g. 104–688 copies/ml) and one isolated positive sample (at day 650) with 8580 copies/ml (Table 1).
In 27 CMV DNA positive patients, all plasma samples with more than 100 CMV DNA copies/ml were analyzed for CMV gB typing. CMV gB typing was successful for 19 patients including four patients with triple CMV infection (1× gB1 + 2 + 3, 1× gB1 + 3 + 4, 2× gB2 + 3 + 4), seven patients with double CMV infection (3× gB1 + 2, 3× gB2 + 3, 1× gB3 + 4) and eight patients in which only one gB type (8x gB3) could be detected. The most prevalent genotype was gB3 (84%; 16 out of 19 patients) followed by gB2 (47%), gB1 (26%) and gB4 (21%). In patients triplly or doublly infected by CMV, peak CMV DNA (mean, 7293 copies/ml; range, 250–32088) was higher than in patients with single CMV infection (mean, 1394 copies/ml; range, 171–8580).
With the introduction of HAART in 1996, the overall incidence of opportunistic infections has declined and survival after an AIDS-defining event has improved. However, rates of CMV disease remain high for the first 3 months before declining . According to literature, the risk of CMV disease is highly correlated with the CMV DNA load in the blood. This is well studied in different groups of immunocompromised transplant recipients [12–14] with two threshold levels in use. CMV-seronegative patients are at risk for CMV disease with high CMV DNA loads above 10.000 copies/ml. CMV-seropositive patients (like most HIV-positive patients) are at risk for CMV disease with very high CMV DNA levels above 100 000 copies/ml. In our study, we focused on the measurement of quantitative CMV DNA loads in plasma (as marker of the risk for the development of CMV disease) during ongoing HAART treatment in correlation with the HIV-1 viral load and CD4 cell count at the same time. These parameters were analyzed in ART-naive patients, before and during the first 2 years of HAART treatment.
In this study of 132 HAART treated patients, 105 (80%) patients presented with undetectable CMV loads (<100 copies/ml) in all of their plasma samples during 2-year follow-up. This already is a first indication of a declining risk for CMV disease in HAART treated patients. In only 27 of 132 (20%) patients, was CMV DNA more than 100 copies/ml found in at least one plasma sample. Focusing on the total number of samples (n = 1348), in only 50 plasma samples (3.7%) CMV DNA more than 100 copies/ml was found: 37 in the range 100–1000 (low), 9 in the range 1000–10000 (moderate) and only four samples with high CMV DNA more than 10 000 (with a highest value of 32 088). In individuals with advanced HIV infection, Erice et al.  found an increased risk for CMV disease in patients with CMV-DNA levels of more than 100 000 copies/ml, although a substantial number of patients suffer from CMV disease with CMV-DNA levels significantly lower than this value [16,17]. In critically ill immunocompetent intensive care units, Limaye et al.  found CMV-DNA levels of more than 1000 copies/ml independently associated with hospitalization or death. According to our results, CMV DNA exceeding these different thresholds is unlikely (<1%) in HAART-treated HIV-patients. The combination of both findings, firstly that most HAART treated patients have undetectable CMV DNA levels in plasma, and secondly that high CMV DNA levels in plasma are very rare, illustrates a dramatic but beneficial decrease in risk for CMV disease during HAART. In practice, the remaining risk is almost limited to those patients who fulfil all three criteria of only during the first 3 months of HAART, only patients with CD4 cell levels less than 250 × 106 cells/l during HAART and only as long as HIV-1 viral load is still detectable (>50 copies/ml).
According to the literature, in addition to CMV disease characterized by high or very high CMV DNA plasma levels, some patients initiating antiretroviral therapy experience an immune reconstitution inflammatory syndrome (IRIS) [19,20]. Both noninfectious diseases and infections, including CMV, are associated with IRIS in HIV-infected patients [19,20]. The interval between onset of HAART and IRIS is highly variable, but is usually less than 8 weeks [21,22]. In our study, the timing of the rebound in CMV DNA during the first 3 months of HAART coincidences with the timing of IRIS in the literature. Also an initial lower CD4 cell count favors the possibility of IRIS in these patients. However, despite the fact that rebound CMV DNA can reach more than 1000 to more than 10 000 copies/ml, an eventual relationship between CMV DNAemia and IRIS is not well established and needs further research.
Previous studies have shown that the gB genotype is correlated with the course of CMV disease in bone marrow transplant recipients and AIDS patients [23–25] and infections with HCMV gB type 1 were previously correlated with a more favorable outcome than infections with gB types two to four when HIV-infected patients were analyzed [23,24]. However, both geographic and demographic differences between patients affect gB distribution and should be considered before associations of gB genotypes and virulence are made . In our study within HAART-treated patients in the Netherlands between 1997 and 2004, CMV gB3 was most prevalent with 16 strains (84%) isolated, followed by CMV gB2 (47%), gB1 (26%) and gB4 (21%). This is different from our previous finding that, even in the same hospital and in an included period (1997–1998), there was a clear predominance of 53% CMV gB1 strains and only 18% CMV gB3 strains in renal transplant recipients . Therefore, these two studies, including 135 HIV-1 patients and 69 renal transplant recipients  within the same hospital, clearly indicate that the distribution of CMV gB subtypes can differ, not only between different geographic regions, but also between different patient groups in the same geographic region. Preexisting immunity to one strain of CMV will not necessarily be protective against infection with another strain of the virus [28–32] as illustrated in our study encompassing multiple patients with PCR-proven double or even triple CMV infection with higher CMV DNA levels in plasma.
CMV disease during HAART is very unlikely as soon as the HIV-1 viral load becomes undetectable (<50 copies/ml) and/or CD4 cell levels are restored to more than 250 × 106 cells/l. Within Dutch HAART-treated patients, infection with CMV gB3 is most prevalent, but double or triple infection with other CMV gB strains is also common.
Contributors: VG, CB and AV contributed to the study concept and design. VG was the study coordinator and performed analysis and interpretation of data. VG, IL and AV actively collected data in the field. AV performed the clinical evaluation. VG and IL performed the virological evaluation. PW performed the CMV loads, HIV loads and CMV genotyping. CB led the writing of the paper, and all investigators participated in its final writing and editing. None of the authors had a personal or financial conflict of interest.
1. Palella FJ Jr, Delaney KM, Moorman AC, Loveless MO, Fuhrer J, Satten GA, et al
. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med 1998; 338:853–860.
2. Ledergerber B, Egger M, Erard V, Weber R, Hirschel B, Furrer H, et al
. AIDS-related opportunistic illnesses occurring after initiation of potent antiretroviral therapy: the Swiss HIV Cohort Study. JAMA 1999; 282:2220–2226.
3. Griffiths PD. CMV as a cofactor enhancing progression of AIDS. J Clin Vir 2006; 35:489–492.
4. Wolff AJ, O'Donnell AE. Pulmonary manifestations of HIV infection in the era of highly active antiretroviral therapy. Chest 2001; 120:1888–1893.
5. Crum NF, Blade KA. Cytomegalovirus retinitis after immune reconstitution. AIDS Read 2005; 15:186–188.
6. Steininger C, Puchhammer-Stöckl E, Popow-Kraupp T. Cytomegalovirus disease in the era of highly active antiretroviral therapy (HAART). J Clin Virology 2006; 37:1–9.
7. Nieuwkerk PT, Sprangers MA, Burger DM, Hoetelmans RM, Hugen PW, Danner SA, et al
. Limited patient adherence to highly activate antiretroviral therapy for HIV-1 infection in an observational cohort. Arch Intern Med 2001; 161:1962–1968.
8. Barbi M, Binda S, Caroppo S, Primache V, Dido P, Guidotti P, et al
. CMV gB genotypes and outcome of vertical transmission: study on dried blood spots of congenitally infected babies. J Clin Virol 2001; 21:75–79.
9. Tarrago D, Quereda C, Tenorio A. Different cytomegalovirus glycoprotein B genotype distribution in serum and cerebrospinal fluid specimens determined by a novel multiplex nested PCR. J Clin Microbiol 2003; 41:2872–2877.
10. Wolffs P, Adams H, Bruggeman C, Goossens V. Comparison of different methods for genotyping of human cytomegalovirus
. In: Abstract Book European Meeting on Molecular Diagnostics
, 18th and 19th October 2007, Scheveningen, the Hague, the Netherlands, 2007:32.
11. Furrer H, Fux C. Opportunistic infections: an update. J HIV Ther 2002; 7:2–7.
12. Aitken C, Barrett-Muir W, Millar C, Templeton K, Thomas J, Sheridan F, et al
. Use of molecular assays in diagnosis and monitoring of cytomegalovirus disease following renal transplantation. J Clin Microbiol 1999; 37:2804–2807.
13. Cope AV, Sabin C, Burroughs A, Rolles K, Griffiths PD, Emery VC. Interrelationships among quantity of human cytomegalovirus (HCMV) DNA in blood, donor-recipient seorstatus, and administration of methylprednisolone as risk factors for HCMV disease following liver transplantation. J Infect Dis 1997; 176:1484–1890.
14. Gor D, Sabin C, Prentice HG, Vyas N, Man S, Griffiths PD, et al
. Longitudinal fluctuations in cytomegalovirus load in bone marrow transplant patients: relationship between peak virus load, donor/recipient serostatus, acute GVHD and CMV disease. Bone Marrow Transplant 1998; 21:597–605.
15. Erice A, Tierney C, Hirsch M, Caliendo AM, Weinberg A, Kendall MA, et al
. Cytomegalovirus (CMV) and human immunodeficiency virus (HIV) burden, CMV end-organ disease, and survival in subjects with advanced HIV infection (AIDS clinical trials group protocol 360). Clin Infect Dis 2003; 37:567–578.
16. Bowen EF, Sabin CA, Wilson P, Griffiths PD, Davey CC, Johnson MA, et al
. Cytomegalovirus (CMV) viraemia detected by polymerase chain reaction identifies a group of HIV-positive patients at high risk of CMV disease. AIDS 1997; 11:889–893.
17. Spector SA, Hsia K, Crager M, Pilcher M, Cabral S, Stempien MJ. Cytomegalovirus (CMV) DNA load is an independent predictor of CMV disease and survival in advanced AIDS. J Virol 1999; 73:7027–7030.
18. Limaye AP, Kirby KA, Rubenfeld GD, Leisenring WM, Bulger EM, Neff MJ, et al
. Cytomegalovirus reactivation in critically ill immunocompetent patients. JAMA 2008; 300:413–422.
19. Murdoch DM, Venter WDF, Van Rie A, Feldman C. Immune reconstitution inflammatory syndrome (IRIS): review of common infectious manifestations and treatment options. AIDS Res Ther 2007; 4:9.
20. Dhasmana DJ, Dheda K, Ravn P, Wilkinson RJ, Meintjes G. Immune reconstitution inflammatory syndrome in HIV-infected patients receiving antiretroviral therapy. Drugs 2008; 68:191–208.
21. Cooney EL. Clinical indicators of immune restoration following highly active antiretroviral therapy. Clin Infect Dis 2002; 34:224–233.
22. Cheng VC, Yuen KY, Chan WM, Wong SS, Ma ES, Chan RM. Immunorestitution disease involving the innate and adaptive response. Clin Infect Dis 2000; 30:882–892.
23. Bongarts A, von Laer D, Vogelberg C, Ebert K, van Lunzen J, Garweg J, et al
. Glycoprotein B genotype of human cytomegalovirus: distribution in HIV infected patients. Scand J Infect Dis 1996; 28:447–449.
24. Rasmussen L, Hong C, Sherman D, Zipeto D, Chou S, Merigan T. Distribution of CMV glycoprotein UL55 (gB) and UL75 (gH) sequence variant groups in patients infected with HIV
. In: Program and abstracts of the Fifth International Cytomegalovirus Conference (Stockholm, Sweden)
. Stockholm: Norstedts Tryckeri, 1995:74.
25. Shepp DH, Match ME, Ashraf AB, Lipson SM, Millan C, Pergolizzi R. Cytomegalovirus glycoprotein B groups associated with retinitis in AIDS patients. J Infect Dis 1996; 174:184–187.
26. Zipeto D, Hong C, Gerna G, Zavattoni M, Katzenstein D, Merigan TC, Rasmussen L. Geographic and demographic differences in the frequency of human cytomegalovirus gB genotypes 1-4 in immunocompromised patients. AIDS Res Hum Retroviruses 1998; 14:533–536.
27. Goossens VJ, Christiaans MH, Blok MJ, Terporten PH, Sillekens P, Lukacsi A, et al
. Onset and duration of cytomegalovirus immediate early 1 mRNA expression in the blood of renal transplant recipients. J Med Virol 2004; 72:94–101.
28. Boppana SB, Rivera LB, Fowler KB, Mach M, Britt WJ. Intrauterine transmission of cytomegalovirus to infants of women with preconceptional immunity. N Engl J Med 2001; 344:1366–1371.
29. Chou SW. Reactivation and recombination of multiple cytomegalovirus strains from individual organ donors. J Infect Dis 1989; 160:11–15.
30. Chou SW. Neutralizing antibody responses to reinfecting strains of cytomegalovirus in transplant recipients. J Infect Dis 1989; 160:16–21.
31. Meyer-Konig U, Schrage B, Huzly D, Bongarts A, Hufert FT. High variability of cytomegalovirus glycoprotein B gene and frequent multiple infections in HIV-infected patients with low CD4 T-cell count. AIDS 1998; 12:2228–2230.
32. Meyer-Konig U, Ebert K, Schrage B, Pollak S, Hufert FT. Simultaneous infection of healthy people with multiple human cytomegalovirus strains. Lancet 1998; 352:1280–1281.